These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32814946)

  • 1. Temocillin dosage adjustment in a preterm infant with severe renal disease: a case report.
    Dumangin G; Brenkman M; Pape E; Kolodziej A; Gambier N; Vrillon I; Charmillon A; Scala-Bertola J
    J Antimicrob Chemother; 2020 Dec; 75(12):3652-3655. PubMed ID: 32814946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Delory T; Gravier S; Le Pluart D; Gaube G; Simeon S; Davido B; Piet E; Lepeule R; Lesprit P; Lafaurie M
    Int J Antimicrob Agents; 2021 Jul; 58(1):106361. PubMed ID: 34000372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Temocillin and urinary tract infections].
    Vallée M; Bruyère F; Roblot F; Brureau L
    Prog Urol; 2017 Oct; 27(12):609-617. PubMed ID: 28869169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
    Soubirou JF; Rossi B; Couffignal C; Ruppé E; Chau F; Massias L; Lepeule R; Mentre F; Fantin B
    J Antimicrob Chemother; 2015 May; 70(5):1466-72. PubMed ID: 25564564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temocillin. In vitro antibacterial activity.
    Slocombe B; Cooper CE; Griffin KE; White AR
    Drugs; 1985; 29 Suppl 5():49-56. PubMed ID: 3849425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of temocillin against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urinary tract infections in France.
    Duployez C; Loïez C; Cattoen C; Wallet F; Vachée A
    Med Mal Infect; 2019 Feb; 49(1):47-53. PubMed ID: 30396720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Temocillin.
    Alexandre K; Fantin B
    Clin Pharmacokinet; 2018 Mar; 57(3):287-296. PubMed ID: 28849402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of temocillin and 15 other agents, including fosfomycin and colistin, against Enterobacteriaceae in Hong Kong.
    Ip M; Lai CK; Fung KSC; Wong KT; Zhu C; Van de Velde S; Tsang DN; Hawkey P
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2491-2494. PubMed ID: 28840351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.
    Balakrishnan I; Awad-El-Kariem FM; Aali A; Kumari P; Mulla R; Tan B; Brudney D; Ladenheim D; Ghazy A; Khan I; Virgincar N; Iyer S; Carryn S; Van de Velde S
    J Antimicrob Chemother; 2011 Nov; 66(11):2628-31. PubMed ID: 21810837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of ceftriaxone and temocillin on fecal abundance of extended-spectrum β-lactamase producing Escherichia coli in a mouse model.
    Chenouard R; Mahieu R; Luque Paz D; Marion E; Eveillard M; Dubée V
    PLoS One; 2021; 16(3):e0248177. PubMed ID: 33690674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods.
    Alexandre K; Réveillon-Istin M; Fabre R; Delbos V; Etienne M; Pestel-Caron M; Dahyot S; Caron F
    J Antimicrob Chemother; 2018 Jul; 73(7):1848-1853. PubMed ID: 29635629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacterales isolated in Poland.
    Kuch A; Zieniuk B; Żabicka D; Van de Velde S; Literacka E; Skoczyńska A; Hryniewicz W
    Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1185-1191. PubMed ID: 32096107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration.
    Laterre PF; Wittebole X; Van de Velde S; Muller AE; Mouton JW; Carryn S; Tulkens PM; Dugernier T
    J Antimicrob Chemother; 2015 Mar; 70(3):891-8. PubMed ID: 25433006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units.
    Glupczynski Y; Huang TD; Berhin C; Claeys G; Delmée M; Ide L; Ieven G; Pierard D; Rodriguez-Villalobos H; Struelens M; Vaneldere J
    Eur J Clin Microbiol Infect Dis; 2007 Nov; 26(11):777-83. PubMed ID: 17668253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden.
    Edlund C; Ternhag A; Skoog Ståhlgren G; Edquist P; Östholm Balkhed Å; Athlin S; Månsson E; Tempé M; Bergström J; Giske CG; Hanberger H;
    Lancet Infect Dis; 2022 Mar; 22(3):390-400. PubMed ID: 34756180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates.
    Alexandre K; Soares A; Chau F; Fantin B; Caron F; Etienne M
    J Antimicrob Chemother; 2019 May; 74(5):1323-1326. PubMed ID: 30689887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing Escherichia coli.
    Alexandre K; Chau F; Guérin F; Massias L; Lefort A; Cattoir V; Fantin B
    J Antimicrob Chemother; 2016 Jul; 71(7):1899-904. PubMed ID: 27029848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion.
    Ngougni Pokem P; Wittebole X; Collienne C; Rodriguez-Villalobos H; Tulkens PM; Elens L; Van Bambeke F; Laterre PF
    Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.
    Miranda Bastos AC; Vandecasteele SJ; Spinewine A; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2018 Jun; 73(6):1630-1638. PubMed ID: 29579214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.